MTRNR2L13

Across TCGA pan-cancer cohorts, MTRNR2L13 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MTRNR2L13 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher MTRNR2L13 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTRNR2L13 expression acts as an unfavorable survival marker.

COAD and UCEC are the cancer types where MTRNR2L13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	0.028	0.781	<.001	30	view →
UCEC	OS	Median	II,III,IV	0.231	0.768	.010	24	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MTRNR2L13–COAD (DFS)

Open the COAD breakdown →